Choline PET or PET/CT and biochemical relapse of prostate cancer: A systematic review and meta-analysis

Clinical Nuclear Medicine

Volumn 38, Issue 5, 2013, Pages 305-314

  Evangelista, Laura ^a   Zattoni, Fabio ^b   Guttilla, Andrea ^b   Saladini, Giorgio ^a   Zattoni, Filiberto ^b   Colletti, Patrick M ^c   Rubello, Domenico ^d  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

biochemical recurrence; choline PET; meta analysis; prostate cancer

Indexed keywords

CHOLINE; CHOLINE C 11; CHOLINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANTIANDROGEN THERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CHOLINE UPTAKE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; LYMPH NODE METASTASIS; META ANALYSIS; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; RADICAL RETROPUBIC PROSTATECTOMY; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

AGED; AGED, 80 AND OVER; ANDROGENS; CHOLINE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; RECURRENCE;

EID: 84876413392     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182867f3c     Document Type: Review

References (61)

1. Roberts SG, Blute ML, Bergstralh EJ, et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001;76:576-581.
2. Aus G, Abbou CC, Bolla M, et al. European Association of Urology. Eur Urol. 2005;48:546-551.
3. Morgan WR, Bergstralh EJ, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology. 1993; 41:113-120.
4. Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis. 2004;7:211-216. (Pubitemid 41741505)
5. Stamey TA, Ferrari MK, Schmid HP. The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol. 1993;150:1856-1859. (Pubitemid 24350816)
6. Boccon-Gibod L, Djavan DW, Hammerer P, et al. Management of prostatespecific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract. 2004;58:382-390. (Pubitemid 38714445)
7. Bott SR, Ahmed HU, Hindley RG, et al. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int. 2010;106:1607-1611.
8. Cher ML, Bianco FJ Jr, Lam JS, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 1998;160:1387-1391. (Pubitemid 29480523)
9. Sella T, Swarthz LH, Swindle PW, et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology. 2004;231:379-385. (Pubitemid 38552892)
10. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296:2329-2335. (Pubitemid 44749360)
11. Flanigan RC, McKay MT, Olson M, et al. Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology. 1996;48:428-432. (Pubitemid 26317484)
12. Seltzer MA, Barbaric Z, Belldegrun A, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol. 1999;162:1322-1328. (Pubitemid 29428572)
13. Rigatti P, Suardi N, Briganti A, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients with radical prostatectomy with biochemical recurrence and nodal recurrence detected by (11C)choline positron emission tomography/ computed tomography. Eur Urol. 2011;60:935-943.
14. Winter A, Uphoff J, Henke R, et al. First results of [11C]choline PET/CTguided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy. Urol Int. 2010; 84:418-423.
15. Kotzerke J, Volkmer B, Neumaier B, et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1380-1384. (Pubitemid 44392221)
16. Martorana G, Schiavina R, Corti B, et al. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol. 2006;176:954-960. (Pubitemid 44142558)
17. Vees HBS, Albrech S, Khan H, et al. 18F-choline and 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int. 2007;99:1415-1420. (Pubitemid 47164795)
18. Rinnab L, Buchegger F, Simon J, et al. [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Urol Int. 2008;81:191-197.
19. Richter JA, Rodriguez M, Rioja J, et al. Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer ralpse after radical treatment. Mol Imaging Biol. 2010;12:210-217.
20. Kwee SA, Coel MN, Lim J. Detection of recurrent prostate cancer with 18-fluorocholine PET/CT in relation to PSA level at the time of imaging. Ann Nucl Med. 2012;26:501-507.
21. Hodolic M. Role of 18F-choline PET/CT in evaluation of patients with prostate carcinoma. Radiol Oncol. 2011;45:17-21.
22. Rinnab L, Simon J, Hautmann RE, et al. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol. 2009;27:619-625.
23. Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet. 1997;350: 185-186. (Pubitemid 27303630)
24. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
25. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ. 2003;327:557-560.
26. Zamora J, Abraira V, Muriel A, et al. Mata-Disc: a software for meta-analysis of test accuracy data. BMC Med Res Methodolol. 2006;6:31.
27. Giovacchini G, Picchio M, Coradeschi E, et al. Predictive factors of (11C)choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:301-309.
28. Panebianco V, Schiarra A, Lisi D, et al. Prostate cancer: 1HMRS-DCEMR at 3T versus (18F)choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol. 2012;81:700-708.
29. Reske SN, Blumstein NM, Glatting G. (11C)choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2008;35:9-17. (Pubitemid 350234137)
30. Bertagna F, Abuhilal M, Bosio G, et al. Role of 11C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation. Jpn J Radiol. 2011;29:394-404.
31. Souvatzoglou M, Krause B, Purschel A, et al. Influence of 11C-choline PET/ CT on the treatment planning for salvage radiation therapy in patients with biocehmical recurrence of prostate cancer. Radiother Oncol. 2011;99: 193-200.
32. Scattoni V, Picchio M, Suardi N, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423-429. (Pubitemid 46963456)
33. Husarik DB, Mirabell R, Dubs M, et al. Evaluation of (18F)-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:253-263.
34. Schilling D, Schlemmer HP, Wagner PH, et al. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int. 2008;102:446-451. (Pubitemid 352032836)
35. Rinnab L, Mottaghy FM, Blumstein NM, et al. Evaluation of (11C)-choline positron-emission/computed tomography in patients with increasing prostatespecific antigen levels after primary treatment for prostate cancer. BJU Int. 2007;100:786-793. (Pubitemid 47360183)
36. Fuccio C, Castellucci P, Schiavina R, et al. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med. 2010;24:485-492.
37. Picchio M, Spinapolice EG, Fallanca F, et al. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:13-26.
38. Fuccio C, Castellucci P, Schiavina R, et al. Role of 11C-choline PET/CT in the restaging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol. 2012;81:e893-e896.
39. de Jong IJ, Prium J, Elsinga PH, et al. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 2003;44:32-39. (Pubitemid 36741372)
40. Pelosi E, Arena V, Skanjeti A, et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med. 2008;113:895-904.
41. Schillaci O, Calabria F, Tavolozza M, et al. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2012;39:589-596.
42. Giovacchini G, Picchio M, Briganti A, et al. (11C)choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence of conventional imaging. J Urol. 2010;184:938-943.
43. Castellucci P, Fuccio C, Rubello D, et al. Is there a role for 11C-choline PET/ CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase G1.5 ng/ml? Eur J Nucl Med Mol Imaging. 2011;38:55-63.
44. Krause BJ, Souvatzoglou SM, Tuncel M, et al. The detection rate of (11C)choline PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008; 35:18-23. (Pubitemid 350234152)
45. Castellucci P, Fuccio C, Nanni C, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394-1400.
46. Cimitan M, Bortolus R, Morassut S, et al. (18F)fluorocholine PET/CT imaging for the detection of recurrent cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33:1387-1398. (Pubitemid 44885404)
47. Picchio M, Briganti A, Fanti S, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur J Urol. 2011;59:51-60.
48. Giovacchini G, Picchio M, Parra RG, et al. Prostate-specific antigen velocity versus prostate specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med. 2012;37:325-331.
49. Giovacchini G, Picchio M, Scattoni V, et al. PSA doubling time for prediction of 11C-choline PET/CT findings in prostate cancer patients with biochemical failure after prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37: 1106-1116.
50. Graute V, Jansen N, Ubleis C, et al. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging. 2012; 39:271-282.
51. Henninger B, Vesco P, Putzer D, et al. (18F)choline positron emission tomography in prostate cancer patients with biochemical recurrence after radical prostatectomy: influence of antiandrogen therapy-a preliminary study. Nucl Med Commun. 2012;33:889-894.
52. Giovacchini G, Breeuwsma AJ. Restaging prostate cancer patients with biochemical failure with PET/CT and radiolabeled choline. Q J Nucl Med Mol Imaging. 2012;56:354-366.
53. Partin AW, Pearon JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994;43:649-659. (Pubitemid 24145607)
54. Trapasso JG, deKernion JB, Smith RB, et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994;152:1821-1825. (Pubitemid 24322638)
55. Lange PH, Ercole CJ, Lightner DJ, et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol. 1989;141: 873-879. (Pubitemid 19108662)
56. Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/ computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA G 5 ng/ml? Mol Imaging Biol. 2006;8:43-48. (Pubitemid 44193401)
57. Steiner C, Vees H, Zaidi H, et al. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin. 2009;48:1-9.
58. Picchio M, Messa C, Landoni C, et al. Value of (11C)choline positron emission tomography for re-staging prostate cancer: a comparison with (18F)fluorodeoxyglucose-positron emission tomography. J Urol. 2003;169: 1337-1340. (Pubitemid 36323779)
59. Marzola MC, Chondrogianis S, Ferretti A, et al. Role of 18F-choline PET/CT in biochemically relpased prostate cancer after radical prostatectomy. Clin Nucl Med. 2013;38:e26-e32.
60. Breeuwsma AJ, Pruim J, van den Bergh ACM, et al. Detection of local, regional, and distant recurrence in patients with PSA relapse after externalbeam radiotherapy using 11C-choline positron emission tomography. Int J Radiat Oncol Biol Phys. 2010;77:160-164.
61. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med. 2010;52:81-89.